Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Weighted Average): 2018-2025

Historic Shares Outstanding (Weighted Average) for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $94.2 million.

  • Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) rose 17.67% to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year increase of 17.67%. This contributed to the annual value of $92.7 million for FY2024, which is 38.83% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) is $94.2 million, which was up 0.53% from $93.7 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $94.2 million during Q3 2025, with a 5-year trough of $33.0 million in Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $78.9 million (2024), whereas its average is $75.6 million.
  • Data for Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 46.35% (in 2024) over the last 5 years.
  • Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $47.5 million in 2021, then rose by 13.29% to $53.8 million in 2022, then grew by 24.14% to $66.8 million in 2023, then spiked by 38.83% to $92.7 million in 2024, then increased by 17.67% to $94.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $94.2 million in Q3 2025, compared to $93.7 million in Q2 2025 and $93.0 million in Q1 2025.